NEW YORK, NY / ACCESSWIRE / November 23, 2020 / In just 5 short years, Jera Foster-Fell, also known as Jera Bean, went from a passionless office job to finding her calling as an influencer, content creator, and social media coach – all while making 6 figures a year, helping over 70 students graduate, and being named one of the top social media coaches of 2020.

In 2015, Jera recalls being in a dark period, wrought with anxiety, a lack of passion, and no friends to lean on. While scrolling through Instagram, on a whim, she bought a popular workout program from a health influencer she was following. This was a huge turning point as now, Jera finally had something positive and grounding in her life.

"I needed something positive and something grounding in my life and after years of struggle, and I found something that I finally felt excited about. The same day that I started the guide, I also created an instagram account to hold myself accountable. I instantaneously found so much joy in it. I found myself connecting daily to other women and it felt amazing to have a physical outlet in my life. And then, out of nowhere, I started to gain followers very quickly," Jera says.

Her account wasn't created with the goal of becoming an influencer – in fact, Jera notes that the word "influencer" didn't even exist back then. Nevertheless, within three months, Jera had amassed 10k followers, and within six months, she decided to leave her office job.

"I loved fitness, I loved social media, my following was growing- I knew that I could do something with all of these components," Jera says.

For two years, Jera was a SoulCycle instructor, learning more about the fitness industry and how to connect with clients. In 2018, she left SoulCycle to pursue content creation full-time, leading to the creation of her signature coaching course, The Social Media Saloon. The course is a three month group coaching program where Jera teaches business owners and creators how to master instagram by solidifying their online presence, building their communities, and turning followers into clients.

Her pivot toward social media coaching was motivated by two factors. Firstly, Jera looked at her goals from a strategic personal standpoint, asking herself if she wanted to be an influencer in ten years when she's 40 years old.

"Looking back on all of my pivots, and looking at how quickly the world of social media changes, I knew that anything could happen between now and when I'm older. I wanted to make a smart choice for my future by adding an additional revenue stream," Jera explains.

Secondly, Jera was motivated by something larger than herself and her future goals – she was motivated by her love of helping others.

"I get a profound sense of joy from helping other people and improving other people's lives. It's something that has always been important to me in some shape or form. When I combined that notion with realizing that I was full of social media knowledge, I knew I could harness the power of that to help others master these platforms that have become so ingrained in our lives and crucial to our businesses," Jera outlines.

With so many communities relying on social media to connect with others, especially during a pandemic, Jera sees the value in making it understandable to her clients. So many of us can tend to look at social media as complicated or a huge frustration, or at its best, a necessary thorn in their side. This apprehension is what Jera is trying to work against by teaching business owners and content creators not just how to use social media, but how to harness it as a powerful and positive tool.

Within the next year, you'll be able to follow Jera as she conquers a whole new platform – TikTok.

"TikTok is no longer just a platform for cute dances and lip syncing, so I'm excited to help business owners harness the potential power of this platform! From a business standpoint, TikTok is absolutely a great strategic platform to use, hence why I will be creating a course around it. Because of the potential for organic reach, it's great for brand awareness," Jera says.

With so much success in her professional life, within the next year, Jera aims to create more time for herself this upcoming year, unrelated to business.

"Working 12+ hour days for 7 days a week was the type of hustle necessary for me to launch and grow my business, but it's not sustainable. I'm learning more and more that I have to fill my own cup in order to continue to help others fill theirs," Jera says.

Be sure to follow Jera on Instagram and TikTok, and check out all her coaching services at the website here.

CONTACT:
Paula Henderson
202-539-7664
phendersonnews@gmail.com

About VIP Media Group:
VIP Media Group is a hybrid PR agency. Their diverse client base includes top-class entrepreneurs, public figures, influencers, and celebrities.

SOURCE: VIP Media Group

ReleaseID: 617994

AUSTIN, TX / ACCESSWIRE / November 23, 2020 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that its management team will participate in the 32nd Annual Piper Sandler Healthcare Conference.

December 1-2, 2020

32nd Annual Piper Sandler Healthcare Conference

Apollo management will participate in virtual one on one meetings. A fireside chat overview presentation has been pre-recorded and will be available to Piper Sandler clients.

Investors interested in attending the virtual presentation or arranging meetings should contact their respective Piper Sandler representative or Apollo's investor relations, Matt Kreps of Darrow Associates, mkreps@darrowir.com.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal complications to the treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.

Apollo's common stock is traded on the Nasdaq Global Market under the symbol "APEN". For more information regarding Apollo Endosurgery, go to: www.apolloendo.com.

Contacts:

Apollo Endosurgery, Inc.
Stefanie Cavanaugh, 512-279-5100
investor-relations@apolloendo.com

Darrow Associates Investor Relations
Matt Kreps, 214-597-8200
mkreps@darrowir.com

SOURCE: Apollo Endosurgery, Inc.

ReleaseID: 617985

LITTLETON, CO / ACCESSWIRE / November 23, 2020 / Ur-Energy Inc. (NYSE American:URG)(TSX:URE) announces that its Chairman and CEO, Jeffrey Klenda, will present at the H.C. Wainwright Mining Conference. The conference is being held virtually on November 30 – December 1, 2020.

Mr. Klenda will provide an overview of the Company's business during the presentation. He also will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Ur-Energy's presentation will begin at 4:00 p.m. ET on Monday, November 30, 2020.

If you are an institutional investor, and would like to attend Ur-Energy's presentation, please click on the following link (www.hcwevents.com/mining) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with Mr. Klenda.

About Ur-Energy

Ur-Energy is a uranium mining company operating the Lost Creek in-situ recovery uranium facility in south-central Wyoming. We have produced, packaged and shipped more than 2.6 million pounds from Lost Creek since the commencement of operations. Applications are under review by various agencies to incorporate our LC East project area into the Lost Creek permits and to operate at our Shirley Basin Project. Ur-Energy is engaged in uranium mining, recovery and processing activities, including the acquisition, exploration, development and operation of uranium mineral properties in the United States. Shares of Ur‑Energy trade on the NYSE American under the symbol "URG" and on the Toronto Stock Exchange under the symbol "URE." Ur-Energy's corporate office is in Littleton, Colorado; its registered office is in Ottawa, Ontario. Ur-Energy's website is www.ur-energy.com.

FOR FURTHER INFORMATION, PLEASE CONTACT

Jeffrey Klenda
Chairman & CEO
866-981-4588
Jeff.Klenda@Ur-Energy.com

SOURCE: Ur-Energy Inc.

ReleaseID: 617984

TORONTO, ON / ACCESSWIRE / November 23, 2020 / StageZero Life Sciences, Ltd. (TSX:SZLS) ("StageZero" or the "Company") announced today an operational update on its COVID-19 testing and operations.

"We are pleased with the Quarter and the tremendous amount of hard work our team has put into making this the Company's largest quarter ever in revenue." said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. "We have significantly upgraded our capabilities through increasing the number of laboratory staff, aggressively building up an inventory of supplies, paying down the accounts payable and introducing new tests. We have also greatly increased the number of groups we are now testing for and expect this to contribute to revenue growth as we move forward."

Operational Highlights

Revenue increase of more than four times all of 2019.
$1.5 million cash received significantly exceeds projected operating costs of $900,000 per quarter.
Partnered with more than 50 groups on testing (Q2: 5 groups).
Momentum in testing is continuing into Q4.
Announced preferred lab status for the Government of Barbados for COVID-19 testing to begin to safely allow tourist air travel to commence.
Partnered with Ichor Blood Services to process tests for players in the IIHF World Junior Championships.
Introduced at home collection for PCR testing using saliva and monitored via telehealth.
Introduced a respiratory panel (Cost of $725).
Expanding laboratory footprint and automation in preparation for Aristotle introduction.

Our partner Ichor Blood Services announced today an expansion of COVID-19 testing (https://www.newswire.ca/news-releases/ichor-blood-services-expands-covid-19-travel-testing-program-to-include-travel-to-hawaii-885018751.html) with an agreement with the State of Hawaii as well as initiation of testing for travel to China.

The Company reports its revenue on a cash received basis. This is in accordance with standard accounting practices in the US for laboratories that bill customers and insurance. As a result, some revenue generated in one quarter will be reported in the next or following quarters. The Company's cash balance at the end of September 30, 2020 was US$1.79M.

The Company will schedule an analyst update call following completion of its current prospectus offering.

The Company's financial statements and management discussion and analysis are available on www.sedar.com.

About StageZero Life Sciences, Ltd.

StageZero Life Sciences is dedicated to the early detection of multiple disease states through whole blood. The Company operates a CAP accredited and CLIA certified high complexity reference laboratory based in Richmond, Virginia. A specialist in PCR testing for the early identification of Cancer through blood, the Company is uniquely positioned to provide both COVID PCR testing (swab) and blood test analysis (Antibody testing). Our full service, telehealth platform includes access to physicians and phle1.7botomist who can prescribe and draw samples for individuals and groups. As we provide COVID-19 test during this Pandemic, we continue making progress with our mission to eradicate late stage cancers through early detection. Our next generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. www.stagezerolifesciences.com

A preliminary prospectus containing important information relating to the securities described in this document has been filed with the securities regulatory authorities in Ontario, British Columbia and Alberta. A copy of the preliminary prospectus, and any amendment, is required to be delivered with this document.

The preliminary prospectus is still subject to completion. There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the final prospectus has been issued.

This document does not provide full disclosure of all material facts relating to the securities offered. Investors should read the preliminary prospectus, the final prospectus and any amendment for disclosure of those facts, especially risk factors relating to the securities offered, before making an investment decision.

Forward-Looking Statements

This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Company Contacts:

James R. Howard-Tripp
Chairman & CEO
jht@stagezerols.com
Tel: 1-855-420-7140 Ext. 1

Rebecca Greco
Investor Relations
rgreco@stagezerols.com
Tel: 1-855-420-7140 Ext. 1838

SOURCE: StageZero Life Sciences Ltd.

ReleaseID: 617932

Brian Hynes isn't your typical entrepreneur. Having practiced law for over twenty-two years, Brian Hynes put it all on the line in 2018 to focus on his finance businesses. Featured in an exclusive interview with IdeaMensch, Brian Hynes reveals some of his top secrets behind his continuous professional success.

CHICAGO, IL / ACCESSWIRE / November 23, 2020 / Brian Hynes was interviewed for IdeaMensch, a digital interview platform for entrepreneurs and industry leaders. With the purpose of helping innovative individuals bring their stories to life, IdeaMensch shared some of Brian Hynes' most valuable pieces of advice.

While Brian was still practicing law, he founded several speciality finance companies including Vendor Assistance Program, LLC (VAP), MuniBuy LLC, Bluestone Capital Markets and Blue Stone Finance. Based in a belief that maintaining good relationships and strong people skills can help you grow your business, Brian Hynes successfully purchased over $6 billion of sovereign and government receivables. As the Founder and Manager of each entity, Brian Hynes credits his success to staying open minded and listening to multiple perspectives.

Another secret to Brian Hynes' success? Waking up early. "My day always starts by 5am. I usually read, workout and prep for the day. Once 9am hits, I'm on the phone all day." When outlining a habit that makes Brian more productive as an entrepreneur, he explained that you shouldn't listen to the critics. Brian Hynes understands that not everyone you meet is going to believe in your idea, but "you have to believe in what you are doing. If you don't really believe in what you're doing, then something new is never going to get done."

Brian Hynes explained that his mistakes are what have made him who he is today: "I tried to launch a hedge fund-of-funds in 2008. It was horrible timing and a venture that effectively bankrupted me. I didn't let this failure define me. Rather I picked myself up and looked into what existing problem I could find a solution for. This is the foundation for every successful entrepreneur."

Lastly, the interview ties up with a particularly relevant piece of advice for anyone struggling during the COVID-19 pandemic: "During moments of crisis, chaos or storm, I always maintain that ‘everything will be fine.'"

Those interested in reading the full interview can do so here.

About Brian Hynes

Brian Hynes earned his undergraduate degree from the University of Illinois and his law degree from Loyola University Chicago. After practicing law for twenty-two years, Brian has now re-directed his focus to finding success in the financial landscape.

While practicing law, Brian founded various specialty finance companies including Vendor Assistance Program, LLC (VAP), MuniBuy, LLC, Bluestone Capital Markets and Blue Stone Finance. Collectively those companies have purchased over $6B of sovereign, government receivables.

Contact

Cody Williams
cwilliams@vendorassistance.com

SOURCE: Brian Hynes

ReleaseID: 617942

Data using XPRIZE supplied contrived fluid samples provides results comparable to those seen in the FDA lab testing of donor saliva, as DECN competes for the $5 million prize and GLOBAL validation

LOS ANGELES, CA / ACCESSWIRE / November 23, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) www.decisiondiagnostics.co, a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters along with its subsidiary Pharma Tech Solutions, Inc., the inventor/manufacturer of the GenViro! Covid-19 Swift Kit truly rapid testing methodology, today announced the results of the completion of its testing for the world-renown XPRIZE, www.xprize.org. The results from the GenViro! testing, using simulated Covid samples and protocols provided by XPRIZE, provided results in 4-9 seconds that were consistent with what the company reports seeing in the FDA lab human donor testing it is concluding at its certified lab and from human donor tests run in the laboratory of its Korean partner.

XPRIZE is the world's leader in designing and operating incentive competitions to solve humanity's grand challenges, in collaboration with OpenCovidScreen, a non-profit founded by scientists and business leaders to drive needed innovation through "Open Science." OpenCovidScreen, was founded along with a coalition of partners calling for the global community to develop accurate, frequent, fast-turnaround, affordable, and easy-to-use screening tests to detect Covid-19 occurrences before they become outbreaks. The $5 million XPRIZE Rapid Covid Testing competition is designed to accelerate the development of high-quality Covid-19 testing that is low cost, reliable, easy to use, and has a fast fast-turnaround, thereby enabling frequent testing.

"While we were guarded about working in the limited time frame provided for the testing on previously unknown and "contrived" samples, we nevertheless anticipated doing especially well on the testing given our faith and belief in our product. I am more than pleased, pleasantly surprised I would add, with the resulting data," said CEO Keith Berman. "We remain more than emboldened about the overall efficacy of the GenViro! Swift Kits. The results provided an identification dichotomy, perhaps for the first time giving rise to a testing category nomenclature for our noteworthy GenViro! Swift product."

DECN's subsidiary Pharma Tech Solutions, conducted its XPRIZE testing at the laboratory of its Korean partner, using the 88 samples provided by the XPRIZE committee. The week-long testing period included two days needed to thaw out the samples, which were received frozen in dry ice. Samples were triple tested in a blind study under the protocols set by the committee. The results have been submitted to the XPRIZE committee for consideration as a finalist, and their announcement is tentatively planned for release on or around December 8th.

The XPRIZE Rapid Covid Testing competition calls on the world's brightest, most innovative minds to develop new, low-cost testing solutions that range from testing devices with 15-minute results to distributed lab testing methods with "next morning" results. Frequent, fast-turnaround, easy-to-use testing enables effective data-driven tracing and isolating strategies. Many currently available Covid-19 tests remain expensive, slow, invasive, and are supply-chain limited. XPRIZE Rapid Covid Testing aims to meet the need to scale testing capabilities by approximately 100-times above our current standards, the level needed to more safely return to everyday activities, especially in times of increased community spread.

To amplify its impact, a $50 million "COVID Apollo Project" led by experienced life sciences investors and company builders – including RA Capital, Bain Capital, Perceptive Advisors, Redmile Group, and Samsara Biocapital – will work with OpenCovidScreen, the XPRIZE community, and others to accelerate the best ideas, technologies, and innovations to market and scale them.

Teams can compete in one of the following four categories: At Home, Point-of-Care, Distributed Lab, or High-Throughput Lab. To ensure supply chain diverse solutions, entries are encouraged in a variety of underlying testing approaches (PCR, Isothermal/LAMP/RPA, CRISPR, Antigen-detection, Next Generation Sequencing, and other technologies). Entries will be judged on overall innovation of solution, appropriate performance, turnaround time, scaling properties and frequency enabled, ease-of-use and cost of solution.

Seven major national and regional health plans are collaborating as founding partners of XPRIZE Rapid Covid Testing: Blue Shield of California, Cambia Health Solutions, Inc, Health Care Service Corporation, GuideWell Mutual Holding Corporation, Horizon Healthcare Services, Inc. (NJ), BlueCross BlueShield of South Carolina. The Anthem Foundation and Anthem, Inc., serve as the Founding Anchor Partners. Supporting partners include leading healthcare, laboratory and technology companies: Google, Amazon, Ilumina, Ancestry, Thermo Fisher Scientific, Exact Sciences, Centerview Partners, Twist Bioscience, Opentrons, HudsonAlpha Institute for Biotechnology, and Testing For America.

ABOUT DECISION DIAGNOSTICS CORP
Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN's products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. With newly inspired technology, and diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $15+ billion at-home testing market.

The company's new GenViro!™ products designed to test for Covid-19 are not yet available in the United States and hopefully should soon be available in Puerto Rico, but Emergency (EUA) Waivers are in process with the U.S. FDA with additional submissions to take place in the near future. The company has also signed an agreement with an FDA and CLIA certified US, Pennsylvania-based testing partner to complete testing per current FDA guidelines and continues to look forward to the FDA authorization of its EUAs.

Beyond all of our testing activities, the company has received word from several of its large GenUltimate! blood glucose product distributors who are seeking to have GenViro! added to their Amazon product offerings upon FDA approval. Currently, Amazon only offers special licenses for point of care and professional use medical products, which would preclude the individual use GenViro! Kit from being available on Amazon, even after FDA approval is secured. Two of the company's GenUltimate! product distributors have these "professional use" arrangements with Amazon, with a third distributor application in the works, although the company may determine that it is in its best interest to offer limited exclusivity to one distributor once FDA authorization is achieved.

The company continues to recruit and accept applications from prospective domestic and international distributors. Inquiries can be directed to info@decisiondiagnostics.co.

Forward-Looking Statements:
This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of November 20, 2020, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.

CONTACT INFORMATION:
Decision Diagnostics Corp.
info@decisiondiagnostics.co
www.genultimate.com
www.genultimatetbg.com
www.pharmatechdirect.com

ADDITIONAL CONTACT INFORMATION:
Decision Diagnostics Corp.
Shep Doniger 561-637-5750
sdoniger@bdcginc.com

XPRIZE
XPRIZE, a 501(c)(3) nonprofit, is the global leader in designing and implementing innovative competition models to solve the world's grandest challenges. Active competitions include the $20 Million NRG COSIA Carbon XPRIZE, the $10 Million Rainforest XPRIZE, the $10 Million ANA Avatar XPRIZE, the $5 Million IBM Watson AI XPRIZE and the $5 Million XPRIZE Rapid Reskilling. For more information, visit xprize.org.

ABOUT THE XPRIZE PANDEMIC ALLIANCE
The XPRIZE Pandemic Alliance is a global coalition that combines the power of collaboration, competition, innovation, and radical thinking to accelerate solutions that can be applied to Covid-19 and future pandemics. For information about the XPRIZE Pandemic Alliance and to join the fight, please visit covid19.xprize.org.

SOURCE: Decision Diagnostics Corp.

ReleaseID: 617804

TORONTO, ON and NEW YORK, NY / ACCESSWIRE / November 23, 2020 / Binovi Technologies Corp., (Binovi) (TSXV:VISN)(OTCQB:BNVIF), a leader in neuro-vision performance technology, is pleased to provide a corporate update.

Key Highlights:

Binovi Platform Engagement: Active Users
Strategic Acquisitions: Vima Rev Strobe Lenses

"Based on current performance and our experience and feedback from users, we expect to have a strong upcoming fiscal year. Our new technologies and acquisitions are primed to move us forward and bring greater innovation, better results for our users, and increased revenues for the company. The team at Binovi has the drive and determination to make great strides in the months and years to come," said Terry Booth, Binovi Executive Chairman.

Binovi Platform Engagement:

The growth of the Binovi Platform is a core focus of the company. Since the launch of Binovi, more than 800 organizations have been registered and have used the platform for vision therapy, sports vision performance. These organizations have created nearly 31,000 users, together completing more than 400,000 active sessions centered around the Binovi Library list of activities, custom activities created by our member organizations.

The company has successfully focused its marketing efforts on the continued expansion of its global relationships while activating local and regional strategic partnerships that support its scalability. Binovi continues to monitor the realities Covid-19 and its impact on healthcare delivery.

Binovi was founded to optimize the delivery of secure healthcare solutions globally, and that has never been more important than today. Our expanding team has ensured that the company is well positioned to leverage the dynamic marketplace that now exists under the restrictions of social distancing.

Strategic Acquisitions:

The acquisition and integration of the VIMA Rev Strobe Lenses under the Binovi umbrella has provided Binovi with an additional toolset to expand its offering. Developed by Nike's (NYSE: NKE) former Global Director of Vision Science and his team of sport science experts, the VIMA Rev Strobe Lenses are an integrated strobe training system that stimulates neuro-cognition through vision training. The lightweight, durable eyewear has been refined over three decades.

VIMA's technology is being integrated into the Company's Binovi Product Platform, with several orders already fulfilled. Current VIMA Rev strobe users include the NHLs Colorado Avalanche, the NBAs Golden State Warriors, Chicago Bulls and the Milwaukee Bucks. Additionally, several significant military installations utilize the strobe technology.

For additional information on the Binovi Connect App, please visit https://www.binovi.com/investor-reports/

@BinoviVISN – Twitter & Instagram

About Binovi Technologies Corp.

Binovi is a best-in-class neuro-visual platform designed to test, analyze, track, and report on individual vision and cognitive performance. Binovi combines hardware, software, specialized expert knowledge, and unique data insights to deliver customized, one-on-one training and learning protocols ideal for K-12 Students, Sports Performance testing and training, and other areas of specialized care. Designed for vision optimization and the enhancement of skills related to cognitive performance, Binovi provides measurable results in less time, and with less effort. Binovi is currently used in over 20 countries.

On Behalf of the Board of Directors

Terry Booth

Executive Chairman

Adam Cegielski

Founder | CEO

Investor Relations

Email: invest@binovi.com
Toll-free: 1 (844) 866-6162
https://www.binovi.com/investor-reports/

Forward looking information:

Certain statements contained in this news release constitute "forward-looking information" as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company's financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company's financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company's continuous disclosure filings filed under the Company's profile at www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Binovi Technologies Corp.

ReleaseID: 617898

Two Unique Product lines offering Solutions for Consumers:

Stink Genie Ozone Surface/Air Disinfectant and Balanced2Day (B2D) for Health and Wellness

LAS VEGAS, NV / ACCESSWIRE / November 23, 2020 / Megola, Inc. (OTC PINK:MGON) (the "Company"), a Consortium Group of Health Technologies and Services Company is pleased to offer product lines to help combat the impact of the Covid -19 pandemic. The company offers both a portable multi-purpose ozone generator for Surface Disinfecting/Deodorizing/Sanitizing and Air Quality control and a CBD product line "Balanced2Day (B2D)" for Health and Wellness that can help alleviate potential long-term effects of Covid-19 infection.

"In keeping with recent studies and news about the benefits of Ozone and CBD, and the benefits of these products to assist in combating COVID-19, we are excited to offer our two unique products; The Stink Genie and Balanced2Day CBD extracts. Offering consumers opportunities to stay safe and achieve mental wellness is important and our brands are designed to reduce the risk of contracting Covid-19 through disinfecting solutions and to improve mental health of consumers by offering the wellness benefits of CBD during their recovery. We offer best in class products at affordable prices." states Megola CEO Robert Gardiner. "Our products are available now at GenieBrands.com and Balanced2Day.com."

CBD and COVID-19

In recent months, several CBD-focused companies have begun studies to determine if CBDs can be used to treat symptoms of COVID-19, which has infected nearly 21M worldwide. In the last two months alone:

A study by Augusta University (GA) have completed animal studies suggesting CBDs could provide positive results for acute respiratory distress syndrome 1
A preclinical study by the University of Lethbridge in Alberta, Canada indicates a number of CBD strains could impact COVID-19 infections 2
The University of Nebraska and Texas Biomedical Research Institute have stated CBDs could treat lung infections in COVID-19 patients 3
The University of Maryland School of Medicine has established a lab specifically to study the effect of CBDs on COVID-19 as an anti-inflammatory 4

_____________________________________________________

OZONE and COVID-19

National Ozone Association (NOAI) released:

On March 12, 2020, the National Ozone Association (NOAI) released the following statement regarding ozone as an agent for killing the current strain of coronavirus: "[O]zone has been proven to kill numerous types of viruses. This includes previous versions of the coronavirus. Admittedly, treating the COVID-19 is yet to be proven for nearly every sanitizing product on the market. So, we are relying on the several past versions of SARS, Bird Flu, and MERS to support the belief that previous sanitizing methods will also sanitize the COVID-19 virus. … Unlike treating mold, pest, or heavy odors; killing pathogens does not require a strong dose of ozone. Treatments of about an hour or two should be enough to kill bacteria and viruses on surfaces." 5

NOAI advises that "short ozone treatments are therefore easy to apply. Set the timer for an hour and spend a little time outside the house or building. Combine routine ozone treatments with proper cleaning and sanitizing already in place, handwashing, and controlling infection hotspots for maximum effect." 5

The Stink Genie is a portable, multi-purpose product that compliments existing disinfectant protocols with the help of ozone, is made in the United States and is simple to use only requiring the user to: Plug In, Set Timer, Walk Away

Recent Megola News

https://alo-gem.com/megola-enters-cbd-market-with-its-premium-hemp-extract-products/
https://alo-gem.com/megolas-disinfectant-deodorizing-sanitizing-portable-ozone-unit-known-to-kill-viruses/

For more information on Balanced2Day: Balanced2Day.com
For more information on The Stink Genie: GenieBrands.com

Outstanding Shares 196,095,060
Certificates Outstanding 23,097,844
Common Shares Float 172,997,216

For more information Contact:
Megola, Inc.
Attn: John MacLeod
http://megolacorp.com
http://twitter.com/megolacorp
megola2020@gmail.com
1-888-587-1698

Stock information here: https://www.otcmarkets.com/stock/MGON/overview.

Disclaimer: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this press release. Additional information respecting the factors that could materially affect the Company and its operations are contained in its annual report on Form 10K and Form 10-Q as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statement.

1 Augusta University – CBD may help avert lung destruction in COVID-19
2 Preclinical study by the University of Lethbridge in Alberta – CBD strains could impact COVID-19 infections
3 University of Nebraska and Texas Biomedical Research Institute – CBDs could treat lung infections in COVID-19 patients
4 University of Maryland School of Medicine – Effect of CBDs on COVID-19 as an anti-inflammatory
5 National Ozone Association https://noai.org/node/611

SOURCE: Megola, Inc.

ReleaseID: 617892

Forges Ahead in Quest to Build the First Compliant Blockchain for Digital Asset Securities

NEW YORK, NY / ACCESSWIRE / November 23, 2020 / Prometheum (www.prometheum.com), a FINRA and SEC regulated end-to-end blockchain ecosystem for the issuance, trading, clearing, settlement, and custody of digital asset securities, today announced its acquisition of a licensed broker-dealer authorized to offer securities to the public via different capital-raising regulations including Reg A+. The acquisition is subject to regulatory approval, and the terms of the transaction are not disclosed. Additionally, Prometheum announces its recent approval of its wholly-owned transfer agent, Spark Transfer Services Inc. With these two milestones, Prometheum forges ahead in its quest to build the first compliant blockchain ecosystem for digital asset securities.

Founded by top Wall Street securities attorneys, Prometheum has successfully leveraged its deep expertise in regulation and securities to create compliant blockchain innovation for issuers, retail investors, and financial professionals. Today's acquisition announcement of a registered broker-dealer furthers Prometheum's reach, offering retail (non-accredited), accredited investors, and institutions the opportunity to invest in digital asset offerings and enabling blockchain-based companies to raise capital compliantly through Prometheum's proprietary issuance platform. Capital formation is vital for the new generation of blockchain native companies to grow and advance distributed ledger technology. With the acquisition, Prometheum will have the ability to offer companies multiple capital raising avenues through the issuance and distribution of compliant digital asset securities.

With the approval of Prometheum's transfer agent, Spark Transfer Services Inc., Prometheum adds to its growing suite of blockchain compatible services for investors and institutions. Companies that issue digital asset securities on Prometheum's offering platform will now have the option to use Spark Transfer Services. Transfer agent services go hand in hand with issuing securities. Companies who raise capital compliantly via a registration or an exemption must report transactions and ownership records related to their securities to the SEC through an SEC-registered transfer agent.

"We are proud to announce our major steps forward in establishing the first compliant blockchain ecosystem for digital asset securities," said Prometheum Co-CEO Aaron Kaplan. "We founded Prometheum three and a half years ago on the belief that Federal Securities Laws are proper and the most complete framework to advance the digital asset securities market. We have remained steadfast in our vision of creating a compliant ecosystem that enables investors to integrate and invest in digital assets seamlessly. Our continued progress is a testament to the hard work of our team and our approach to leveraging the Federal Securities Laws and structure of the financial services industry to allow any investors to participate in the digital asset universe."

Prometheum has updated its Regulation A+ offering to reflect its recent advances in technology and acquisitions, including the licensed broker-dealer acquisition and Spark Transfer Services, as well as key hires and related business processes as it nears SEC qualification. For more information, please contact contact@prometheum.com.

About Prometheum

Founded in 2017 by a group of Wall Street lawyers, Prometheum is an innovative blockchain company engaged in building the first compliant end-to-end ecosystem for compliant digital assets. Digital asset securities are born and traded on the network, where the Prometheum blockchain tracks transactions for secure clearing and settlement within 24 hours.

About Spark Transfer Services Inc.

Spark Transfer Services is an SEC registered transfer agent that aims to use blockchain technology to generate reports and perform other transfer agent services.

Prometheum, Inc. Disclaimer

The offering, after qualification by the SEC, will be made only by means of the Offering Circular. Any information in this press release or any other communication shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification for sale as provided in Regulation A+ in any such state or jurisdiction.

You may obtain a copy of the Preliminary Offering Circular and the offering statement in which such Preliminary Offering Circular was filed with the SEC by visiting: https://www.sec.gov/cgi-bin/browse-edgar?company=Prometheum&owner=exclude&action=getcompany.

Leadership
Aaron Kaplan, Founder and Co-CEO
Benjamin Kaplan, Founder and Co-CEO

CONTACT:

Jacque Silva
Caliber Corporate Advisers
917.880.2464
jacqueline@calibercorporateadvisers.com

SOURCE: Prometheum

ReleaseID: 617749